Paroxysmal Nocturnal Hemoglobinuria

 Paroxysmal Nocturnal Hemoglobinuria:

When to Suspect, How to Diagnose, and Strategies to Treat

Dr Neeraj Manikath , claude.ai

ABSTRACT

Paroxysmal Nocturnal Hemoglobinuria (PNH) is a rare, acquired clonal hematopoietic stem cell disorder characterized by complement-mediated intravascular hemolysis, thrombophilia, and bone marrow failure. Despite advances in diagnosis and therapy, PNH remains underdiagnosed due to its protean manifestations and rarity. This review synthesizes current understanding of PNH pathophysiology, highlights clinical pearls for early recognition, delineates modern diagnostic algorithms, and discusses treatment paradigms including complement inhibition. Special emphasis is placed on bedside clinical clues, diagnostic pitfalls, and practical management strategies relevant to practicing internists and hematologists.

Keywords: Paroxysmal nocturnal hemoglobinuria, complement-mediated hemolysis, thrombosis, eculizumab, flow cytometry, bone marrow failure

INTRODUCTION

Paroxysmal Nocturnal Hemoglobinuria was first described over a century ago by Paul Strübing in 1882, yet it continues to challenge clinicians with its diverse presentations and life-threatening complications. With an estimated prevalence of 1-5 cases per million, PNH occurs across all ages and ethnicities, with a median age at diagnosis of approximately 35-40 years.

The disease arises from a somatic mutation in the phosphatidylinositol glycan class A (PIGA) gene located on the X chromosome. This mutation impairs synthesis of glycosylphosphatidylinositol (GPI) anchors, resulting in absence of complement regulatory proteins CD55 and CD59 on cell surfaces. The unprotected erythrocytes become vulnerable to complement-mediated lysis, while the absence of these proteins on leukocytes and platelets contributes to the thrombotic diathesis that defines PNH's most devastating complication.

PATHOPHYSIOLOGY: THE MOLECULAR BASIS

The GPI Anchor Defect

The PIGA gene encodes an enzyme essential for the first step of GPI anchor biosynthesis. Because PIGA is X-linked, a single somatic mutation in hematopoietic stem cells suffices to produce the phenotype in both males and females. Over 150 different mutations have been identified, all resulting in functional GPI anchor deficiency.

GPI anchors normally tether more than 150 different proteins to cell membranes. In PNH, the critical missing proteins include CD55 (decay-accelerating factor) and CD59 (membrane inhibitor of reactive lysis). CD55 prevents formation of C3 convertases, while CD59 blocks assembly of the membrane attack complex (MAC, C5b-9). Without these safeguards, circulating complement proteins attack the cell membrane, leading to chronic intravascular hemolysis.

Clonal Selection: Why Do PNH Clones Expand?

A fundamental paradox in PNH biology is why cells with defective GPI anchors gain proliferative advantage. The leading hypothesis posits that PNH often arises in the context of immune-mediated bone marrow failure. In aplastic anemia, autoreactive T cells attack hematopoietic stem cells, possibly targeting GPI-anchored proteins as autoantigens.

Clinical Pearl: The overlap between PNH and aplastic anemia is substantial—up to 50% of PNH patients have concurrent or antecedent marrow hypoplasia, and small PNH clones can be detected in 20-70% of aplastic anemia patients. This relationship has profound implications for screening and treatment decisions.

CLINICAL MANIFESTATIONS: THE DIAGNOSTIC CHALLENGE

The Classic Triad (That Isn't Always Present)

Traditional teaching emphasizes hemolytic anemia, thrombosis, and bone marrow failure as the cardinal features of PNH. However, this triad occurs in fewer than 30% of patients at presentation. The disease exists on a spectrum:

Subtype	Clinical Features	Clone Size
Classic PNH	Hemolysis-dominant, signs of intravascular hemolysis	>50% GPI-deficient granulocytes
PNH in setting of AA	Cytopenias predominate, minimal hemolysis	Often <10% GPI-deficient cells
Subclinical PNH	Small clone, minimal/no symptoms	<1-5% GPI-deficient cells

 

Hemolysis: Beyond Dark Urine

While hemoglobinuria remains pathognomonic when present, only 25-50% of patients report this classic symptom. The hemolysis in PNH is predominantly intravascular, resulting in:

Bedside Clue #1: First morning urine is often darkest due to nocturnal acidosis and complement activation during sleep. Ask patients specifically about urine color upon waking—many dismiss intermittent dark urine as 'dehydration.'

Bedside Clue #2: Chronic fatigue disproportionate to the degree of anemia. Free hemoglobin in plasma scavenges nitric oxide, causing smooth muscle dystonia. This manifests as:

• Severe fatigue (>90% of patients)

• Erectile dysfunction in males

• Esophageal spasm and dysphagia

• Abdominal pain (particularly right upper quadrant)

• Headaches

Thrombosis: The Leading Cause of Death

Thrombotic events occur in 30-40% of PNH patients and account for 40-67% of mortality. The thrombotic risk in PNH is distinctly different from other hypercoagulable states:

Critical Recognition Pattern: Thrombosis in unusual sites should trigger PNH consideration:

• Hepatic vein (Budd-Chiari syndrome) – present in 10-20% of PNH

• Portal, splenic, or mesenteric veins

• Cerebral venous sinuses

• Dermal veins (causing painful nodules)

• Concurrent arterial and venous thromboses

Oyster Pearl: In any patient under 45 with Budd-Chiari syndrome, the probability of PNH approaches 50%. Screen every case—even those with other risk factors like oral contraceptives or myeloproliferative neoplasms, as PNH can coexist.

Mechanisms of thrombosis in PNH are multifactorial: complement activation on platelets and endothelium, impaired fibrinolysis, release of procoagulant microparticles from hemolyzed cells, and nitric oxide depletion causing platelet activation and endothelial dysfunction.

Renal Manifestations

Chronic kidney disease develops in 60-65% of PNH patients, driven by:

• Hemosiderin deposition in renal tubules

• Microthrombi in renal vasculature

• Nitric oxide scavenging causing renal vasoconstriction

• Iron deposition

Management Hack: Monitor serum creatinine and urinary protein annually. Early CKD in PNH may be reversible with complement inhibition—another reason for timely diagnosis and treatment.

WHEN TO SUSPECT PNH: THE HIGH-YIELD CLINICAL SCENARIOS

Early diagnosis requires clinical vigilance. Test for PNH in these situations:

Absolute Indications for PNH Testing

1. Unexplained Coombs-Negative Hemolytic Anemia

Particularly if accompanied by reticulocytopenia (suggesting concurrent marrow dysfunction) or elevated LDH disproportionate to hemoglobin level (>3-4 times normal).

2. Hemoglobinuria

Any report of dark, cola-colored, or red-brown urine, especially if intermittent or worse in the morning.

3. Thrombosis in Unusual Sites

Splanchnic vein thrombosis (hepatic, portal, mesenteric), cerebral venous sinus thrombosis, dermal vein thrombosis. Budd-Chiari syndrome in anyone under 60 should prompt immediate PNH testing.

4. Aplastic Anemia or MDS

All patients with aplastic anemia should be screened for PNH clones at diagnosis and during follow-up. Similarly, screen hypoplastic MDS and refractory cytopenia.

5. Refractory Iron Deficiency

Iron deficiency without clear blood loss, particularly with elevated LDH or low haptoglobin. Chronic hemoglobinuria causes urinary iron loss.

Suggestive Clinical Scenarios

• Unexplained severe fatigue or erectile dysfunction with hemolysis

• Dysphagia with hemolytic anemia

• Recurrent abdominal pain with hemolysis

• Pulmonary hypertension with hemolysis

• Thrombosis with concurrent anemia and low haptoglobin

DIAGNOSTIC APPROACH: BEYOND FLOW CYTOMETRY

The Gold Standard: High-Sensitivity Flow Cytometry

Flow cytometry for GPI-anchored proteins is the definitive diagnostic test. Modern high-sensitivity flow cytometry can detect PNH clones as small as 0.01%.

Technical Pearl: Test

granulocytes and monocytes, not erythrocytes, as the primary markers. Erythrocytes have shorter lifespans and may be depleted by hemolysis or masked by transfusions. The standard panel tests:

• CD55 and CD59 on RBCs

• CD16 (FcγRIII), CD24, and FLAER on granulocytes

• CD14 and FLAER on monocytes

FLAER (fluorescent aerolysin) binds directly to GPI anchors and is the most specific reagent for detecting GPI deficiency.

Interpretation Nuances:

• Clone size ≥10% on granulocytes typically causes clinical disease

• Clones 1-10% may be clinically significant in aplastic anemia context

• Type II cells (partial GPI deficiency) and Type III cells (complete deficiency) are both reported; Type III correlates with hemolysis severity

• Monocyte clones often larger than granulocyte clones—use both for accuracy

Supporting Laboratory Tests

Test	Findings in PNH
LDH	Markedly elevated (often >1000 U/L), mirrors hemolytic activity
Haptoglobin	Undetectable in active hemolysis
Reticulocytes	Inappropriately low for degree of anemia if marrow failure present
Direct Coombs	Negative (distinguishes from autoimmune hemolytic anemia)
Urine hemosiderin	Present (Prussian blue stain positive), marker of chronic hemoglobinuria
Serum ferritin	Often low despite hemolysis (iron loss in urine)

 

Diagnostic Pitfall: Ham's test (acidified serum) and sucrose lysis test are obsolete, insensitive, and should never be used in modern practice. They have been entirely replaced by flow cytometry.

TREATMENT STRATEGIES: FROM SUPPORTIVE TO TARGETED

Complement Inhibition: The Paradigm Shift

The introduction of complement inhibitors revolutionized PNH management, transforming a once-fatal disease into a chronic manageable condition.

Eculizumab (Soliris) - a humanized monoclonal antibody targeting C5, preventing formation of the membrane attack complex (MAC).

Dosing: Induction: 600 mg IV weekly × 4 weeks, then 900 mg at week 5. Maintenance: 900 mg IV every 14 days.

Clinical Effects:

• Reduces intravascular hemolysis by 85-90%

• Decreases transfusion requirements dramatically

• Improves quality of life and fatigue scores

• Reduces thrombotic risk significantly

• May stabilize or improve renal function

Critical Pre-Treatment Requirement: ALL patients must be vaccinated against

Neisseria meningitidis at least 2 weeks before starting therapy (or receive prophylactic antibiotics until vaccination is protective). Meningococcal infection is a life-threatening complication with C5 inhibition. Use quadrivalent conjugate vaccine (MenACWY) plus MenB vaccine for comprehensive coverage.

Management Hack for Vaccination: In urgent cases (active thrombosis, severe hemolysis), start penicillin prophylaxis immediately and give vaccines concurrently with first dose. Continue prophylactic antibiotics for 2-4 weeks post-vaccination.

Ravulizumab (Ultomiris) - a next-generation C5 inhibitor with extended half-life allowing every 8-week dosing. Equivalent efficacy to eculizumab with improved convenience. Loading dose based on body weight, followed by maintenance every 8 weeks.

Proximal Complement Inhibitors: Pegcetacoplan (C3 inhibitor) addresses both intravascular and extravascular hemolysis. Dosed subcutaneously twice weekly. May be superior in patients with breakthrough hemolysis on C5 inhibitors.

Indications for Complement Inhibitor Therapy

Strong indications:

• Transfusion-dependent anemia

• Thrombosis (current or history)

• Severe symptoms (fatigue, dysphagia, abdominal pain)

• Renal insufficiency related to PNH

• Pulmonary hypertension

Relative indications:

• Clone size >50% with active hemolysis (LDH >1.5× ULN)

• Pregnancy with PNH (discuss risks/benefits)

Extravascular Hemolysis and C3-Mediated Breakthrough

20-30% of patients on eculizumab develop C3 opsonization of PNH erythrocytes, leading to extravascular hemolysis in the spleen and persistent anemia despite C5 blockade.

Recognition Clues:

• Persistent anemia despite treatment

• Reticulocytosis without hemoglobinuria

• Elevated indirect bilirubin with normal LDH

• Flow cytometry showing C3 deposition on RBCs

Management Options: Switch to proximal complement inhibitor (pegcetacoplan) or dose intensification of C5 inhibitor in select cases.

Anticoagulation

Primary Prophylaxis: The role remains controversial. Consider in:

• Large clone size (>50%) not on complement inhibitor

• High-risk features: previous thrombosis, significant hemoglobinuria, pregnancy

Secondary Prophylaxis: Lifelong anticoagulation after thrombotic event. Warfarin (INR 2-3) or DOACs are both used, though data on DOACs in PNH are limited.

Expert Opinion: Complement inhibition reduces thrombotic risk substantially. Primary prophylactic anticoagulation may not be necessary in patients on eculizumab/ravulizumab without prior thrombosis, but clinical judgment and shared decision-making are paramount.

Supportive Care

Iron Supplementation: Essential in most patients due to chronic urinary iron loss. Oral iron is preferred; IV iron should be used cautiously as it may trigger hemolysis in some patients.

Folic Acid: 1 mg daily to support erythropoiesis.

Transfusions: For symptomatic anemia. Use leukoreduced, washed RBCs when possible to minimize complement activation. Prophylactic steroids before transfusion may reduce hemolytic reactions.

Erythropoietin: May be beneficial in patients with concurrent bone marrow failure or those with inadequate reticulocyte response.

Allogeneic Stem Cell Transplantation

The only curative therapy for PNH. Reserved for:

• Refractory disease despite optimal medical therapy

• Severe aplastic anemia with PNH

• Evolution to myelodysplastic syndrome or acute leukemia (rare)

• Patients who cannot access or afford complement inhibitor therapy

With modern complement inhibitors, transplant is rarely needed for hemolysis control alone. Non-myeloablative regimens are preferred when transplant is indicated.

SPECIAL CLINICAL SITUATIONS

PNH and Pregnancy

Pregnancy dramatically increases thrombotic risk (20-25% of pregnancies in untreated PNH). Maternal mortality approaches 10-12% and fetal loss 10-15%.

Management Approach:

• Complement inhibitor therapy throughout pregnancy (considered safe, Category C)

• Prophylactic anticoagulation (LMWH preferred)

• Continue anticoagulation for 6 weeks postpartum

• Close hematology follow-up

PNH and Surgery

Perioperative period carries increased thrombotic and hemolytic risks.

Perioperative Checklist:

• Ensure complement inhibitor dosing is up-to-date

• Consider prophylactic anticoagulation

• Avoid hypotension and acidosis (triggers hemolysis)

• Use leukoreduced blood products

• Early mobilization postoperatively

MONITORING AND LONG-TERM FOLLOW-UP

Baseline Assessment:

• Complete flow cytometry with clone size on granulocytes, monocytes, RBCs

• CBC with reticulocyte count

• Hemolysis markers (LDH, haptoglobin, indirect bilirubin)

• Iron studies

• Renal function and urinalysis

• Liver imaging if Budd-Chiari suspected

• Bone marrow biopsy (to assess for aplasia, MDS)

On Complement Inhibitor:

• CBC, LDH every 3 months

• Renal function every 6-12 months

• Flow cytometry annually (or if clinical change)

• Monitor for breakthrough hemolysis or extravascular hemolysis

• Meningococcal booster vaccines per guidelines

Red Flag Monitoring: Rising LDH on stable complement inhibitor dosing suggests breakthrough hemolysis—check flow for C3 opsonization and consider dosing adjustment or switch to proximal inhibitor.

PROGNOSIS AND NATURAL HISTORY

Historically, median survival was 10-15 years from diagnosis, with thrombosis as the leading cause of death. The advent of complement inhibition has transformed outcomes:

• 10-year survival on eculizumab approaches 75-80% (vs. 50% historically)

• Thrombotic risk reduced by ~85%

• Quality of life improvements equivalent to general population in many patients

Spontaneous remission is rare (<5%) but documented, typically in small clones associated with aplastic anemia after immunosuppression.

Evolution to MDS/AML: Occurs in 5-10% of patients over 10 years. Higher risk in those with concurrent aplastic anemia or complex karyotype.

EMERGING THERAPIES AND FUTURE DIRECTIONS

Oral Complement Inhibitors: Danicopan (Factor D inhibitor) and iptacopan (Factor B inhibitor) offer oral alternatives to IV therapy. Danicopan is approved as add-on to C5 inhibitors for extravascular hemolysis.

Dual Pathway Inhibition: Combinations targeting both proximal and terminal complement may offer superior hemolysis control.

Gene Therapy: Preclinical studies exploring PIGA gene correction in hematopoietic stem cells show promise but remain investigational.

CONCLUSION

Paroxysmal Nocturnal Hemoglobinuria, though rare, demands clinical recognition given its life-threatening complications and availability of transformative therapies. The astute internist must maintain a high index of suspicion in patients with unexplained hemolysis, particularly when accompanied by atypical thromboses or bone marrow failure. High-sensitivity flow cytometry has made diagnosis straightforward when considered. Complement inhibition has revolutionized outcomes, offering patients near-normal life expectancy and quality of life. As oral complement inhibitors and novel agents emerge, PNH stands as a paradigm of precision medicine—where understanding molecular pathophysiology has directly translated to targeted, life-saving therapy.

 

KEY CLINICAL PEARLS FOR THE PRACTICING INTERNIST   1. Test for PNH in any Budd-Chiari syndrome patient under 60, any unexplained Coombs-negative hemolysis, and all aplastic anemia patients. 2. Dark morning urine is pathognomonic but occurs in only 25-50% of cases—don't wait for it. 3. Severe fatigue disproportionate to anemia suggests nitric oxide depletion from hemolysis. 4. Flow cytometry tests granulocytes/monocytes (not just RBCs) and uses FLAER for highest specificity. 5. Vaccinate against meningococcus before starting complement inhibitors—life-threatening infections can occur. 6. Complement inhibition reduces thrombotic risk by 85% and has transformed PNH from fatal to manageable. 7. Breakthrough hemolysis on C5 inhibitors = check for C3 opsonization and consider switch to proximal inhibitor. 8. PNH in pregnancy requires complement inhibitor + anticoagulation + close monitoring throughout gestation and postpartum.

 

REFERENCES

1. Brodsky RA. Paroxysmal nocturnal hemoglobinuria. Blood. 2021;137(17):2304-2314. doi:10.1182/blood.2020006926

2. Hillmen P, Muus P, Duhrsen U, et al. Effect of the complement inhibitor eculizumab on thromboembolism in patients with paroxysmal nocturnal hemoglobinuria. Blood. 2007;110(12):4123-4128. doi:10.1182/blood-2007-06-095646

3. Schrezenmeier H, Muus P, Socié G, et al. Baseline characteristics and disease burden in patients in the International Paroxysmal Nocturnal Hemoglobinuria Registry. Haematologica. 2014;99(5):922-929. doi:10.3324/haematol.2013.093161

4. Kulasekararaj AG, Hill A, Rottinghaus ST, et al. Ravulizumab (ALXN1210) vs eculizumab in C5-inhibitor-experienced adult patients with PNH: the 302 study. Blood. 2019;133(6):540-549. doi:10.1182/blood-2018-09-876805

5. Hillmen P, Szer J, Weitz I, et al. Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2021;384(11):1028-1037. doi:10.1056/NEJMoa2029073

6. Parker CJ. Diagnosis of paroxysmal nocturnal hemoglobinuria: evolution of the methodology and clinical application. Blood Rev. 2020;44:100669. doi:10.1016/j.blre.2020.100669

7. Hill A, DeZern AE, Kinoshita T, Brodsky RA. Paroxysmal nocturnal haemoglobinuria. Nat Rev Dis Primers. 2017;3:17028. doi:10.1038/nrdp.2017.28

8. Kelly RJ, Hill A, Arnold LM, et al. Long-term treatment with eculizumab in paroxysmal nocturnal hemoglobinuria: sustained efficacy and improved survival. Blood. 2011;117(25):6786-6792. doi:10.1182/blood-2011-02-333997

9. de Latour RP, Mary JY, Salanoubat C, et al. Paroxysmal nocturnal hemoglobinuria: natural history of disease subcategories. Blood. 2008;112(8):3099-3106. doi:10.1182/blood-2008-01-133918

10. Nishimura J, Kanakura Y, Ware RE, et al. Clinical course and flow cytometric analysis of paroxysmal nocturnal hemoglobinuria in the United States and Japan. Medicine (Baltimore). 2004;83(3):193-207. doi:10.1097/01.md.0000126763.68170.46

11. Risitano AM, Notaro R, Marando L, et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood. 2009;113(17):4094-4100. doi:10.1182/blood-2008-11-189944

12. Urbano-Ispizua A, Schrezenmeier H, Einsele H, et al. Allogeneic hematopoietic cell transplantation in paroxysmal nocturnal hemoglobinuria: the EBMT experience. Bone Marrow Transplant. 2019;54(10):1598-1604. doi:10.1038/s41409-019-0463-x

13. Curran KJ, Kernan NA, Prockop SE, et al. Paroxysmal nocturnal hemoglobinuria in pediatric patients. Pediatr Blood Cancer. 2012;59(3):525-529. doi:10.1002/pbc.24095

14. Peffault de Latour R, Fremeaux-Bacchi V, Porcher R, et al. Assessing complement blockade in patients with paroxysmal nocturnal hemoglobinuria receiving eculizumab. Blood. 2015;125(5):775-783. doi:10.1182/blood-2014-03-560540

15. Brodsky RA. Complement in hemolytic anemia. Blood. 2015;126(22):2459-2465. doi:10.1182/blood-2015-06-640995

16. Socié G, Mary JY, de Gramont A, et al. Paroxysmal nocturnal haemoglobinuria: long-term follow-up and prognostic factors. Lancet. 1996;348(9027):573-577. doi:10.1016/S0140-6736(95)12360-1

17. Borowitz MJ, Craig FE, Digiuseppe JA, et al. Guidelines for the diagnosis and monitoring of paroxysmal nocturnal hemoglobinuria and related disorders by flow cytometry. Cytometry B Clin Cytom. 2010;78(4):211-230. doi:10.1002/cyto.b.20525

18. Sutherland DR, Keeney M, Illingworth A. Practical guidelines for the high-sensitivity detection and monitoring of paroxysmal nocturnal hemoglobinuria clones by flow cytometry. Cytometry B Clin Cytom. 2012;82(4):195-208. doi:10.1002/cyto.b.21023

19. Peffault de Latour R, Kulasekararaj A, Iacobelli S, et al. Eltrombopag added to immunosuppression in severe aplastic anemia. N Engl J Med. 2022;386(1):11-23. doi:10.1056/NEJMoa2109965

20. Nishimura JI, Yamamoto M, Hayashi S, et al. Genetic variants in C5 and poor response to eculizumab. N Engl J Med. 2014;370(7):632-639. doi:10.1056/NEJMoa1311084